Quick Nav
Publications
Pharmacy Times
Generic Times News

TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS

Published Online: Thursday, November 1, 2007   [ Request Print ]

Teva Pharmaceutical Industries Ltd has resolved its patent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-based generic drug maker to enter the US market with its generic versions of 3 GSK diabetes drugs: Avandia (rosiglitazone maleate), Avandamet (rosiglitazone maleate and metformin HCl), and Avandaryl (rosiglitazone maleate and glimepiride) oral tablets. Although details of the settlement were held confidential by both parties, it was disclosed that Teva could begin US marketing of the GSK drugs late in the first quarter of 2012. GSK filed several lawsuits challenging Teva?s plans to market generic versions of its drugs, and a trial in federal court had been scheduled to begin in August.


Related Articles
No Result Found




Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-257-0701

Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.
 




Become a Member
Forgot Password?